Lokalize Prostat Kanserine Yaklaşım
Özet
Dünya genelinde erkeklerde en sık görülen ikinci kanser türü olan prostat kanserine ve özellikle lokalize prostat kanserine yönelik güncel yaklaşım ve tedavi yöntemleri makalede detaylıca ele alınmaktadır. Tedavi planlamasında ilk adım evrelemedir ve hastalık lokalize (T1/2/erken T3, N0, M0), lokal ileri veya metastatik olarak sınıflandırılır. Yavaş ilerleme eğiliminde olan lokalize prostat kanserinde, tedavilerin yaşam kalitesine etkileri göz önünde bulundurularak hasta komorbiditeleri ve yaşam beklentisi değerlendirilmelidir. Standart yaklaşımlar arasında izlem tedavileri, radikal cerrahi, radyasyon tedavisi ve odak tedavileri yer alır. İzlem stratejilerinden "Bekle-Gör", semptomatik durumlarda tedaviyi hedeflerken; "Aktif İzlem" ise belirli kriterleri karşılayan hastalarda aşırı tedaviyi önlemek amacıyla serum PSA, mp-MRI ve tekrarlayan biyopsilerle yakın takibi içerir. Cerrahi tarafta radikal prostatektomi açık, laparoskopik veya robot yardımlı uygulanabilmekte, ancak yöntemlerin birbirine üstünlüğüne dair kesin kanıt bulunmamaktadır. Radyoterapi seçeneğinde çevre doku hasarını azaltan IMRT tercih edilirken, brakiterapi de düşük-orta riskli hastalarda doğrudan prostat içine radyoaktif madde yerleştirilerek uygulanır. Son olarak, fokal lazer ablasyonu ve HIFU gibi yenilikçi fokal tedaviler, yan etkileri azaltarak yaşam kalitesini korumayı amaçlasa da henüz klinik araştırma aşamasındadır.
The article thoroughly examines current approaches and treatment methods for localized prostate cancer, which is the second most commonly diagnosed cancer in men globally. Staging is the initial step in treatment planning, classifying the disease as localized (T1/2/early T3, N0, M0), locally advanced, or metastatic. Since localized prostate cancer tends to progress slowly, patient comorbidities and life expectancy must be evaluated, considering the impact of treatments on the quality of life. Standard approaches include surveillance therapies, radical surgery, radiation therapy, and focal treatments. Among surveillance strategies, "Watchful Waiting" targets deferred or symptomatic treatment, whereas "Active Surveillance" involves close monitoring via serum PSA, mp-MRI, and repeat biopsies to prevent overtreatment in eligible patients. Regarding surgery, radical prostatectomy can be performed open, laparoscopically, or robot-assisted, though evidence demonstrating the superiority of any specific method is lacking. In radiotherapy, IMRT is preferred to reduce peripheral tissue toxicity, while brachytherapy is utilized for low-to-medium risk patients by placing radioactive sources directly into the prostate. Lastly, innovative focal treatments like focal laser ablation and HIFU aim to preserve quality of life by minimizing side effects, but they are currently limited to clinical trials.
Referanslar
Culp MBB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol 2020;77:38–52. https://doi.org/10.1016/J.EURURO.2019.08.005.
Sailer VW, Perner S, Wild P, Köllermann J. Localized Prostate Cancer. Pathologe 2022;42:603–16. https://doi.org/10.1007/s00292-021-00997-8.
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–101. https://doi.org/10.1001/JAMA.293.17.2095.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, vd. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71:618–29. https://doi.org/10.1016/j.eururo.2016.08.003.
Brundage MD, Sydes MR, Parulekar WR, Warde P, Cowan R, Bezjak A, vd. Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial. J Clin Oncol 2015;33:2151–7. https://doi.org/10.1200/JCO.2014.57.8724.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, vd. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017;71:618–29. https://doi.org/10.1016/J.EURURO.2016.08.003.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, vd. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375:1415–24. https://doi.org/10.1056/NEJMOA1606220.
Vernooij RWM, Lancee M, Cleves A, Dahm P, Bangma CH, Aben KKH. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane database Syst Rev 2020;6. https://doi.org/10.1002/14651858.CD006590.PUB3.
Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane database Syst Rev 2017;9. https://doi.org/10.1002/14651858.CD009625.PUB2.
Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, vd. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 2015;116:358–65. https://doi.org/10.1111/BJU.12905.
Hickey BE, James ML, Daly T, Soh FY, Jeffery M. Hypofractionation for clinically localized prostate cancer. Cochrane database Syst Rev 2019;9. https://doi.org/10.1002/14651858.CD011462.PUB2.
Weg ES, Pei X, Kollmeier MA, McBride SM, Zelefsky MJ. Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data. Adv Radiat Oncol 2019;4:492–9. https://doi.org/10.1016/J.ADRO.2019.03.012.
Dutta SW, Alonso CE, Libby B, Showalter TN. Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives. Expert Rev Med Devices 2018;15:71–9. https://doi.org/10.1080/17434440.2018.1419058.
Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, vd. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017;14:415–39. https://doi.org/10.1038/NRUROL.2017.76.
Ahdoot M, Lebastchi AH, Turkbey B, Wood B, Pinto PA. Contemporary treatments in prostate cancer focal therapy. Curr Opin Oncol 2019;31:200–6. https://doi.org/10.1097/CCO.0000000000000515.
